Results 1 to 10 of about 11,522 (197)

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic

open access: yesPathogens, 2022
Intravenous (IV) administration of antiviral monoclonal antibodies (mAbs) can be challenging, particularly during an ongoing epidemic, due to the considerable resources required for performing infusions.
Erin Kuang   +17 more
doaj   +3 more sources

Cryo-EM structure of Sudan ebolavirus glycoprotein complexed with its human endosomal receptor NPC1 [PDF]

open access: yesCommunications Biology
Sudan ebolavirus (SUDV), like Ebola ebolavirus (EBOV), poses a significant threat to global health and security due to its high lethality. However, unlike EBOV, there are no approved vaccines or treatments for SUDV, and its structural interaction with ...
Fan Bu   +5 more
doaj   +2 more sources

Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. [PDF]

open access: yesPLoS Pathogens, 2010
Ebolavirus (EBOV) is an enveloped, single-stranded, negative-sense RNA virus that causes severe hemorrhagic fever with mortality rates of up to 90% in humans and nonhuman primates.
Asuka Nanbo   +7 more
doaj   +1 more source

Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development

open access: yesFrontiers in Immunology, 2022
Monoclonal antibodies (mAbs) have proven effective for the treatment of ebolavirus infection in humans, with two mAb-based drugs Inmazeb™ and Ebanga™ receiving FDA approval in 2020.
Charles D. Murin   +5 more
doaj   +1 more source

Ebolaviruses: New roles for old proteins. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2018
In 2014, the world witnessed the largest Ebolavirus outbreak in recorded history. The subsequent humanitarian effort spurred extensive research, significantly enhancing our understanding of ebolavirus replication and pathogenicity.
Diego Cantoni, Jeremy S Rossman
doaj   +1 more source

Ébola, lo que debemos saber

open access: yesRevista Ciencias Biomédicas, 2020
La entidad conocida como ébola, recibe esa denominación por el nombre del río más cercano al distrito africano, donde se presentaron los primeros casos del brote en la década de los setenta del siglo XX (1).
Comité Editorial
doaj   +1 more source

Pathogenicity and Virulence of Ebolaviruses with Species- and Variant-specificity

open access: yesVirulence, 2021
Ebola virus (EBOV), belonging to the species Zaire ebolavirus in the genus Ebolavirus, causes a severe febrile illness in humans with case fatality rates (CFRs) up to 90%.
Satoko Yamaoka, Hideki Ebihara
doaj   +1 more source

Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health Region, Democratic Republic of the Congo.

open access: yesPLoS Neglected Tropical Diseases, 2022
Although multiple antigenically distinct ebolavirus species can cause human disease, previous serosurveys focused on only Zaire ebolavirus (EBOV). Thus, the extent of reactivity or exposure to other ebolaviruses, and which sociodemographic factors are ...
Kelly C L Shaffer   +18 more
doaj   +1 more source

One-Step Reverse-Transcription FRET-PCR for Differential Detection of Five Ebolavirus Species. [PDF]

open access: yesPLoS ONE, 2015
Ebola is an emerging infectious disease caused by a deadly virus belonging to the family Filoviridae, genus Ebolavirus. Based on their geographical distribution, Ebolavirus has been classified into total five species so far, mainly Zaire, Sudan, Taï ...
Guangwu Lu   +6 more
doaj   +1 more source

Development and validation of portable, field-deployable Ebola virus point-of-encounter diagnostic assay for wildlife surveillance

open access: yesOne Health Outlook, 2021
Early detection of Ebola virus spillover into wildlife is crucial for rapid response. We developed and validated a portable, cold-chain independent Ebola virus RT-qPCR assay.
Dania M. Figueroa   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy